Poolbeg Pharma

Poolbeg Pharma is a pharmaceutical company that operates as a clinical-stage infectious disease. It offers POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza, POLB 002, an in­licensed first­-in-­class board spectrum RNA­ based immunotherapy for respiratory virus infections, and POLB 003, an intramuscular vaccine to prevent melioidosis. The company also caters to micro­ and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune-stimulating antigens to various areas of the gut and artificial intelligence-powered drug programs.